Phenominer Database Results (7 results)

 
 
Table "column sort" updates the order of the bars in the chart.
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Average Type Value Units SEM SD Method Method Duration Post Insult Time Value Method Notes Clinical Measurement Notes Experiment Notes Record ID Study ID
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77.0 days-146.0 days 15 median 83.1 d 2.32 9.0 necropsy 0.0 one treatment interleukin-2 111119 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77.0 days-157.0 days 15 median 94.0 d 2.63 10.2 necropsy 0.0 one treatment 5-fluorouracil + interleukin-2 111120 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 98.0 days-164.0 days 18 median 101.3 d 3.87 16.4 necropsy 0.0 two treatments 5-fluorouracil + interleukin-2 111144 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 98.0 days-186.0 days 21 median 122.6 d 2.42 11.1 necropsy 0.0 two treatments 5-fluorouracil + thymosin alpha-1 +interleukin-2 111145 3196
BDIX/OrlIco post-insult time of death due to metastatic liver tumors PROb cells (2 x 10E6 cells) then sodium butyrate (20 mmol/l) (for 7 days) and interleukin-2 (45 x 10E4 IU/kg) (for 5 days) Cordel S, etal., Int J Cancer. 1998 Dec 9;78(6):735-9. doi: 10.1002/(sici)1097-0215(19981209)78:6<735::aid-ijc11>3.0.co;2-6. life span trait male 126.0 days-190.0 days 6 median 66.0 d necropsy 0.0 post-insult time of death due to metastatic liver tumors (CMO:0003882) survival 107420 3085
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77.0 days-147.0 days 14 median 84.0 d 3.61 13.5 necropsy 0.0 one treatment thymosin alpha-1 + interleukin-2 111122 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77.0 days-162.0 days 15 median 98.7 d 2.17 8.4 necropsy 0.0 one treatment 5-fluorouracil + thymosin alpha-1 +interleukin-2 111123 3196